Chikungunya

The Worldwide Insect Repellent Industry is Expected to Reach $11 Billion by 2030 - ResearchAndMarkets.com

Retrieved on: 
Friday, December 30, 2022
Chemicals, Plastics, Manufacturing, Rash, Kao Corporation, Yellow fever, Fever Dream, Mining, Projection, COVID-19, Skin, USD, Growth, Malaria, Health, Fatality, Chikungunya, Vaccine, Agriculture

dengue, chikungunya, and yellow fever are spreading across the globe especially in under-developed countries due to less sanitation awareness is expected to boost the growth of the insect repellent market.

Key Points: 
  • dengue, chikungunya, and yellow fever are spreading across the globe especially in under-developed countries due to less sanitation awareness is expected to boost the growth of the insect repellent market.
  • Additionally, more people are using insect repellent as a result of manufacturers' increased production of goods in consumer-friendly pricing ranges.
  • In terms of insect type, mosquito repellent is projected to have the largest market share in 2021 owing to the growing awareness of mosquito-causing diseases leading to fatality.
  • Insect repellent is expected to witness substantial growth over the forecast period with a CAGR of 10.5% from 2022 to 2030.

Valneva Hosts Investor Day in New York City

Retrieved on: 
Tuesday, December 6, 2022
EBV, Euronext Paris, 2020 European Medicines Agency cyberattack, SRR, Marketing Authorisation Application, Inflation, RSV, BLA, EMA, Developing country, International Air Transport Association, VLA, Epstein–Barr virus infection, Advisory Committee, Food, FDA, Degenerative disease, Medicare Part D, PRV, Saint-Herblain, Chikungunya, Nordic, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Advisory Committee on Immunization Practices, VLA2001, European Medicines Agency, MAA, Mouse, Vaccine, Biologics license application, Human, Marketing, Eastern Time Zone, VBI, Medicare, Pfizer, Infection, Șaeș, Priority review, Growth, IATA, Antigen, Epithelium, COVID-19, Policy, ACIP, Q&A, Pharmaceutical industry, Valneva SE, Lyme disease

Saint-Herblain (France), December 06, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, is hosting an in-person investor day today in New York City to discuss the Company’s current vaccine pipeline, commercial products, and future directions.

Key Points: 
  • Saint-Herblain (France), December 06, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, is hosting an in-person investor day today in New York City to discuss the Company’s current vaccine pipeline, commercial products, and future directions.
  • While completion of the BLA submission is expected by year end, Valneva is focused on pre-commercial and market access preparations.
  • Valneva successfully generated a stabilized pre-fusion F protein antigen, which forms the basis of the proprietary vaccine candidate VLA1554.
  • Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need.

Valneva Reports Positive 12-Month Antibody Persistence Data for Single-Shot Chikungunya Vaccine Candidate

Retrieved on: 
Monday, December 5, 2022
Euronext Paris, European, BLA, Infection, CEPI, EMA, Immunization, Vaccination, Mortality, VLA, Antibody, FDA, Marketing, Safety, Priority, Headache, Nausea, Vaccine, Human, Lyme disease, Fever, Interest group, Food and Drug Administration, LMIC, Disease, Ageing, Rash, SAE, Public health, Genome, Aedes, Alphavirus, Fast track (FDA), File, Dietary supplement, Pharmaceutical industry, Instituto Butantan, Valneva SE, CHIKV, Chikungunya

The antibody persistence trial enrolled 363 healthy adult participants and followed them from month 6 after vaccination to month 12.

Key Points: 
  • The antibody persistence trial enrolled 363 healthy adult participants and followed them from month 6 after vaccination to month 12.
  • These antibody levels confirm the antibody persistence profile observed in an earlier study3.
  • The antibody persistence was similar in older adults aged ≥65 years, who retained neutralizing antibody titers comparable to younger adults throughout the follow-up.
  • VLA1553 is a live-attenuated, single dose vaccine candidate targeting the chikungunya virus, which has spread to over 100 countries.

Comanche Biopharma Announces Appointment of Allison August, M.D., as Chief Medical Officer

Retrieved on: 
Thursday, December 15, 2022
Faculty, Allison, Medical Affairs Bureau, Pritzker School of Medicine, Alpert Medical School, Pregnancy, Chicago (franchise), Paganini Competition, Sirna, Comanche, Patient, Death, Immunization, Disease, Woman, CMV, COVID-19, History, Brown University, Premature, Self-signed certificate, Vaccine, Drug, University, RSV, Mortality, Infant, Health, Harvard Medical School, Bryn Mawr College, Gynaecology, Pharmaceutical industry, Chikungunya, Diagnosis, Pre-eclampsia, Obstetrics, Moderna, Novavax

CONCORD, Mass., Dec. 15, 2022 /PRNewswire/ -- Comanche Biopharma , a preclinical biopharmaceutical company developing a novel siRNA therapy for the treatment of preeclampsia, today announced that maternal health, vaccine and drug development expert Allison August, M.D., has been appointed as the companys Chief Medical Officer.

Key Points: 
  • CONCORD, Mass., Dec. 15, 2022 /PRNewswire/ -- Comanche Biopharma , a preclinical biopharmaceutical company developing a novel siRNA therapy for the treatment of preeclampsia, today announced that maternal health, vaccine and drug development expert Allison August, M.D., has been appointed as the companys Chief Medical Officer.
  • "We are very pleased to have Allison join Comanche.
  • Her academic career included faculty positions at the Brown University Medical School and adjunctive faculty at Harvard Medical School affiliated hospitals.
  • "We are at a unique moment when an effective treatment for preeclampsia may finally be within medical reach," said Johnson.

CEPI Boosts ‘Coronavirus X’ Vaccine Search With Expanded VBI Vaccines Deal

Retrieved on: 
Tuesday, December 6, 2022
Biotechnology, FDA, Other Health, Health, Pharmaceutical, Oncology, Other Science, Research, Infectious Diseases, Science, Clinical Trials, Nipah virus, Interim, Coalition for Epidemic Preparedness Innovations, Infection, Disease, Government of Canada, COVID-19, G7, Risk, Chikungunya, Cytomegalovirus, Virus, National Research Council, Partnership, Coronavirus, Epidemic, Multimedia, Vaccine, COVID-19 vaccine, Severe acute respiratory syndrome coronavirus 2, Glioblastoma, Middle East respiratory syndrome–related coronavirus, Omicron, Hepatitis B, Lassa mammarenavirus, Science, VLP, CEPI, CMV, Severe acute respiratory syndrome coronavirus, Immunity, Nature, COVAX, Immune system, NRC, Rift Valley fever, Pandemic, Research, Annual report, Human coronavirus 229E, Public sector, VBI, News, Safety, G20, GBM, Coalition, Animal, Pharmaceutical industry

The Coalition for Epidemic Preparedness Innovations (CEPI) is expanding its world-leading portfolio of potential variant-proof coronavirus vaccines in a deal with VBI Vaccines Inc. (Nasdaq: VBIV) to advance the development of multivalent coronavirus shots that could be deployed against COVID-19 as well as a future Coronavirus X.

Key Points: 
  • The Coalition for Epidemic Preparedness Innovations (CEPI) is expanding its world-leading portfolio of potential variant-proof coronavirus vaccines in a deal with VBI Vaccines Inc. (Nasdaq: VBIV) to advance the development of multivalent coronavirus shots that could be deployed against COVID-19 as well as a future Coronavirus X.
  • Application of this funding will now be directed into the broader development of the VBI-2900 coronavirus vaccine program to explore the Coronavirus X potential of VBIs technology.
  • We have long recognized the public health value that multivalent vaccines capable of anticipating new variants and coronavirus strains could provide.
  • VBI Vaccines Inc. (VBI) is a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease.

Clover’s Vaccine Candidate Reduced Household Transmission of SARS-CoV-2 in Study Published in Clinical Infectious Diseases

Retrieved on: 
Wednesday, November 30, 2022
Hospital, United Nations Development Programme, Risk, Hepatitis E, Therapy, International Vaccine Institute, Severe acute respiratory syndrome coronavirus 2, Shigella, European Medicines Agency, WHO, Infection, Omicron, United Nations, Aluminium, SCB-2019, National Medical Products Administration, Transcription-mediated amplification, PQ, Development, Public health, Salmonella, Adjuvant, Fever Dream, Chikungunya, Global health, Cholera, World Health Organization, CpG, HPV, 1018, Safety, IVI, Schistosomiasis, MD, Vaccination, 2020 European Medicines Agency cyberattack, Vaccine, Pharmaceutical industry, Clover, COVID-19, Trimer

SHANGHAI, China and SEOUL, Republic of Korea, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutics, and the International Vaccine Institute, an international nonprofit organization devoted to providing vaccines critical to global public health and based in Seoul, Korea, today announced that Clinical Infectious Diseases has published additional data from SPECTRA, a global Phase 2/3 clinical trial, that showed vaccination with SCB-2019 (CpG 1018/Alum) reduced the risk of transmitting SARS-CoV-2 infection to household members, compared to placebo participants.

Key Points: 
  • Among the 134 household contacts of infected household members who had received SCB-2019, there was one case of COVID-19; among the 250 household contacts of infected household members who were not vaccinated, there were 12 cases.
  • There were no cases of symptomatic SARS-CoV-2 infection among household contacts who were partially or fully vaccinated and where the infected household member was vaccinated with SCB-2019.
  • This indicates that SCB-2019 vaccination reduced household transmission and that vaccinated household contacts also likely benefited from the protection provided by their own vaccination.
  • The study team was blinded to the assignment of SPECTRA participants to vaccine or placebo groups.

Valneva to Host Investor Day in New York City

Retrieved on: 
Tuesday, November 29, 2022
Euronext Paris, VLA, Saint-Herblain, Chikungunya, Q&A, Infection, Valneva SE, Vaccine, BLA, Lyme disease, Pfizer

The event will also be webcast live and archived on the Companys website.

Key Points: 
  • The event will also be webcast live and archived on the Companys website.
  • Valneva will also provide an update on its existing commercial business and select pre-clinical development programs, followed by a financial overview.
  • A live Q&A session will follow the formal presentations with opportunity for virtual attendees to participate in the Q&A.
  • Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need.

Emergex Generates Chikungunya Ligandome, a Milestone in the Development of its T cell Adaptive Vaccine

Retrieved on: 
Monday, November 28, 2022
Degenerative disease, MHC, Infection, UK Research and Innovation, Epitope, Public health, Innovation, Peptide, Laboratory, Allele, HLA, RNA, Cell, Developing country, IUK, Alphavirus, Department of Health and Social Care, Global health, Research, Medicine, Disease, UKRI, Government of the United Kingdom, Social work, CD8, Immortalised cell line, Human, DHSC, Organic acid, HLA-C, Vaccine, Pharmaceutical industry, Chikungunya, CHIKV

Abingdon, Oxon, UK, 28 November 2022 Emergex Vaccines Holding Limited (Emergex), a clinical-stage biotechnology company addressing major global infectious diseases through the development of fully synthetic CD8+ T cell Adaptive Vaccines, announces today that it has generated a Chikungunya (CHIKV) ligandome, the first major milestone in the development of Emergexs CD8+ T cell CHIKV Adaptive Vaccine candidate.

Key Points: 
  • Abingdon, Oxon, UK, 28 November 2022 Emergex Vaccines Holding Limited (Emergex), a clinical-stage biotechnology company addressing major global infectious diseases through the development of fully synthetic CD8+ T cell Adaptive Vaccines, announces today that it has generated a Chikungunya (CHIKV) ligandome, the first major milestone in the development of Emergexs CD8+ T cell CHIKV Adaptive Vaccine candidate.
  • The library of CHIKV ligandome peptides identified by Emergex will now enter the next phase of development.
  • Laurens Rademacher, Chief Technology Officer at Emergex commented: The ligandome identified allows the addition of a Chikungunya vaccine candidate to Emergexs pipeline.
  • The ligandome library which contains viral and self MHC class I peptides has been established successfully by using the Emergex proprietary vaccine development platform, which provides a rational basis for CD8+ T cell vaccine development.

Valneva Appoints Dipal Patel as Chief Commercial Officer

Retrieved on: 
Thursday, November 17, 2022
Growth, CCO, Euronext Paris, VLA, Saskatchewan River Sturgeon Management Board, Saint-Herblain, Knowledge, Chikungunya, Travel, Lyme disease, DIPAL Party, Infection, Vaccine, Pharmaceutical industry

Saint-Herblain (France), November 17, 2022 Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced the appointment of Dipal Patel as Chief Commercial Officer (CCO) and Management Board member.

Key Points: 
  • Saint-Herblain (France), November 17, 2022 Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced the appointment of Dipal Patel as Chief Commercial Officer (CCO) and Management Board member.
  • Ms. Patel is an established commercial leader with over 23 years of experience in the pharmaceutical sector covering commercial strategy, execution, market access and lifecycle management.
  • Thomas Lingelbach, Chief Executive Officer of Valneva, said, Dipals addition to our team represents an important and timely step forward in strengthening Valnevas commercial and strategic leadership.
  • Ms. Patel, newly appointed Chief Commercial Officer of Valneva, stated, The last few years have put an increasing focus on the importance of vaccine preventable diseases.

Lemonex, IVI Exchange MOU on Joint Vaccine Development

Retrieved on: 
Thursday, November 10, 2022
COVID-19, Research, Infectious Diseases, Genetics, Biotechnology, Health, Pharmaceutical, Science, Oncology, RNA transfection, Fever Dream, Chikungunya, Vaccine, United Nations, IVI, World Health Organization, Partnership, Administration, Immunotherapy, Research, International Vaccine Institute, Organization, Korea, Epidemiology, Technology, WHO, HPV, United Nations Development Programme, COVID-19, Global health, Cholera, Hepatitis E, RNA, LNP, Goal, Infection, Sirna, Shigella, Schistosomiasis, Public health, CEO, World, Salmonella, PQ, MOU, Pharmaceutical industry

The International Vaccine Institute (IVI) announced on November 10th it signed a memorandum of understanding (MOU) with Lemonex, a company specializing in RNA gene therapy development, and agreed to seek cooperation in research and development.

Key Points: 
  • The International Vaccine Institute (IVI) announced on November 10th it signed a memorandum of understanding (MOU) with Lemonex, a company specializing in RNA gene therapy development, and agreed to seek cooperation in research and development.
  • IVI and Lemonex have agreed to join forces to introduce DegradaBALL drug delivery technology to the development of infectious disease vaccines and advance vaccine development by using IVIs extensive expertise in all areas of vaccine development.
  • The two organizations plan to utilize Lemonex's expertise in vaccine development and drug delivery platform, and rapidly develop a safe and effective mRNA vaccine through mutual cooperation by using IVI's extensive experience in clinical development and epidemiology.
  • Cheolhee Won, CEO of Lemonex, said, We are proud to have established a vaccine R&D partnership with IVI to develop an mRNA vaccine.